NCT05639218View on ClinicalTrials.gov

Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques

Active, not recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

February 17, 2023

Study Completion Date

December 31, 2023

Conditions
Atherosclerotic Cardiovascular Disease
Interventions
DRUG

Inclisiran

Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy

Trial Locations (1)

LV-1002

Pauls Stradins Clinical University Hospital, Riga

All Listed Sponsors
lead

Pauls Stradins Clinical University Hospital

OTHER